The global pain therapeutic injectables market holds a valuation of US$ 19.3 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 19.3 Billion |
| Market Value 2033 | US$ 30.9 Billion |
| CAGR 2023 to 2033 | 4.5% |
| Market Share of Top 5 Countries | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Therapeutic injections for treating pain can aid in reducing swelling and discomfort. Depending on the location, muscle injury, skeletal or neurological structures, and overall symptoms, there are choices for injectable treatment for almost any sort of pain a patient is experiencing. These injections can be administered intravenously, subcutaneously, or through an epidural catheter. These injectables are frequently used to treat acute pain which occurs because of injuries, post-operative pain, or chronic pain due to any kind of illness.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market holds around 28.5% share of the overall global painkillers market with a value of around US$ 67.7 Billion, in 2022.
The increasing prevalence of chronic pain conditions, such as arthritis, cancer pain, and lower back pain, is one of the primary drivers of the pain therapeutic injectables market. These conditions require long-term pain management, which often includes the use of injectable pain medications. Due to the rise in chronic diseases, the market for pain therapeutic injectables has exhibited a consistent increase.
Apart from this, the market is anticipated to expand in the coming years because of the rising number of surgeries performed worldwide. This eventually demands post-operative pain management. Moreover, technological developments have led to improvements in drug delivery systems which ensures more accurate and effective administration of injectable drugs.
As the importance of pain management becomes more widely recognized, patients are seeking out effective pain relief options that can improve their quality of life. Pain therapeutic injectables are one such option that can provide rapid and effective relief from pain.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 30.9 billion in the year 2033.
There are numerous potentials for innovation and expansion in the market for companies dealing in pain therapeutic injectables. The market is being driven by the rising demand for minimally invasive procedures worldwide. Minimally invasive procedures, such as injections, are becoming increasingly popular among patients due to their ability to reduce pain and discomfort while minimizing the risk of complications. This is driving the demand for pain therapeutic injectables, which can provide effective pain relief with minimal invasiveness. The development of this market is anticipated to be aided by a number of new technologies and therapies. Due to their efficiency and patient convenience, injectable pain treatments are anticipated to see increased use.
As the global population ages, the prevalence of chronic pain conditions is expected to increase, which will drive demand for pain therapeutic injectables. The geriatric population is particularly susceptible to chronic pain, making them a key demographic for the pain therapeutic injectables market.
Principal Consultant
The market is constrained by a number of factors, including expensive injectable drug costs, adverse effects from prolonged use of opioids, and the possibility of drug abuse and addiction. Pain therapeutic injectables can be expensive, which can limit access for some patients. This is particularly true for those who do not have adequate health insurance coverage or who are underinsured.
The regulatory environment is also posing difficulties for the market, particularly when it comes to confirming the efficacy and safety of new injectable treatments before they can be released. The development and approval of new pain medications can be a lengthy and expensive process due to the strict regulatory requirements in many countries. This can limit the number of new products entering the market and slow down innovation.
The USA dominates the global region with a total market share of around 39.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
The market for pain therapeutic injectables in the USA is expanding due to a number of factors. One of the contributing aspects is the increasing prevalence of chronic pain. Chronic pain is a major healthcare issue in the United States, affecting millions of people each year. This has led to a growing demand for pain management therapies, including pain therapeutic injectables.
Other than this, an increase in awareness and education regarding the advantages of injectable painkillers such as their quicker onset of action and more accurate dosing, among medical professionals and patients, is driving the market in this region. In USA, the growth of the market is also fueled by the creation of novel and sophisticated injectable medications as well as the increased availability of enhanced delivery methods. These advancements are driving growth in the market by providing better treatment options for patients.
Japan contributed around US$ 1.1 Billion revenue to the global pain therapeutic injectables market in 2022. The prevalence of chronic pain conditions is increasing in Japan, including osteoarthritis, cancer pain, and lower back pain. This has led to a growing demand for pain therapeutic injectables. Additionally, as older people are more likely to have chronic pain, Japan's aging population is fueling the demand for pain management therapies, including pain therapeutic injectables.
The development of this market has also been aided by technological developments and the accessibility of new painkillers and treatments in Japan. The demand for pain treatment injectables in Japan has also been significantly influenced by patients' and healthcare professionals' growing knowledge regarding the importance of effective pain management.
Germany held a market share of 25.6% in the Western Europe pain therapeutic injectables market in 2022.
The market is expanding in Germany due to the growing popularity of minimally invasive procedures for pain management, which frequently involves the use of injectable medications. Other than this, the demand for pain treatment injectables in the nation is also being fueled by the growing importance of at-home healthcare and self-administration of injectables. Overall, it is anticipated that these factors will continue to fuel the market for pain therapeutic injectables in Germany in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Opioids by drug class segment held 53.4% share in the global market in 2022. Opioids are still frequently used to control pain, especially in situations where there is significant acute pain or chronic pain that does not respond to other forms of treatment. In recent years, although there has been a shift towards the use of non-opioid options for pain management, opioids still have a place in some circumstances. Overall, opioids play a substantial role in the market of therapeutic injectables for treating pain, but their usage needs to be carefully regulated and balanced with other therapies.
Prescription drugs by product segment contributed around US$ 11.3 Billion in the global market in 2022. Since they are frequently used to manage pain in individuals who require more intense therapy, prescription medications play a key role in the market of therapeutic injectables for treating pain. The market for pain therapeutic injectables also has a prescription medicine sector that is significant because it offers healthcare professionals a variety of treatment alternatives to fulfill the various demands of their patients.
Surgical pain by indication segment held more than one-third revenue share in the global market in 2022. Injectable painkillers are in high demand because of the increasing prevalence of surgical pain conditions. As a result of tissue damage and inflammation, patients who have undergone surgery, are most likely to experience pain so, pain treatment is a crucial component of post-operative care. Since pain therapeutic injectables can offer more immediate and intense pain relief than oral drugs, these are often utilized to alleviate the discomfort due to the pain.
Retail pharmacies is the leading segment with over 27.0% revenue share in 2022 globally. When it comes to distribution channel, retail pharmacies are considered a place which is quite accessible to patients in order to buy these kinds of injectable drugs. Therefore, retail pharmacies play a significant role in this market. Retail pharmacies typically stock a wide range of medications, including prescription drugs, over-the-counter medications, and other healthcare products. This makes it easy for patients to find the medications they need without having to visit multiple locations.
Key differentiating tactics used by producers of pain therapeutic injectables include an increase in product releases and regulatory body approval, growth into other regions, and marketing approvals in other locations. The dynamics of the market have changed as a result of increasing awareness.
Similarly, recent developments related to companies manufacturing pain therapeutic injectables have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Central Asia, Russia & Belarus, Balkan & Baltic Countries, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia & New Zealand, Japan, China, South Korea, GCC Countries, Kingdom of Saudi Arabia, Türkiye, Northern Africa, South Africa, and Israel |
| Key Market Segments Covered | Drug Class, Product, Indication, Distribution Channel and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The United States, Japan, and China dominate the global pain therapeutic injectables market.
The pain therapeutic injectables market is forecast to register a CAGR of 4.5% through 2033.
The overall global painkillers market has a value of around US$ 19.3 Billion in 2022.
Technological advancement disrupts the current market trends, such as the development of new pain medications and delivery methods.
The global market size of pain therapeutic injectables is to reach US$ 30.9 Billion by 2033.
1. Executive Summary | Pain Therapeutic Injectables Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Patient Treatment Journey
4.2. Disease Epidemiology
4.3. Pipeline Assessment
4.3.1. By Drug Class
4.3.2. Comprehensive Assessment by Phases
4.3.3. Emerging Novel Trends
4.4. List of Key Players, By Region
4.5. Number of Surgeries Performed, By Region
4.6. Key Regulations
4.7. Reimbursement Landscape
4.8. PESTLE Analysis
4.9. Value chain analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Painkillers Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Aging Population
5.2.3. Patent Expiration of Novel Pain Management Drugs (Opioids)
5.2.4. Introduction of Novel Advancements in Pain Therapeutics Injectables
5.2.5. Average Annual Spending on Pain Therapeutics Injectables
5.2.6. Awareness of Pain Therapeutics
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. 2022 Market Scenario
6.2. COVID-19 and Impact Analysis
6.2.1. By Drug Class
6.2.2. By Product
6.2.3. By Indication
6.2.4. By Distribution Channel
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis 2018 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
8.3.1. Opioids
8.3.1.1. Tramadol
8.3.1.2. Oxycodone
8.3.1.3. Hydrocodone
8.3.1.4. Other Opioids
8.3.2. NSAIDs
8.3.3. Local Anesthetics
8.3.4. Acetaminophen
8.4. Market Attractiveness Analysis By Drug Class
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Over-The-Counter (OTC) Products
9.3.2. Prescription Drugs
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
10.3.1. Surgical Pain
10.3.2. Cancer Pain
10.3.3. Neuropathic Pain
10.3.4. Musculoskeletal & Joint Pain
10.3.5. Others
10.4. Market Attractiveness Analysis By Indication
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Specialty Clinics
11.3.3. Long Term Care Centers
11.3.4. Retail pharmacies
11.3.5. Drug Stores
11.3.6. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
12.2. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.2.1. North America
12.2.2. Latin America
12.2.3. Western Europe
12.2.4. Eastern Europe
12.2.5. Russia & Belarus
12.2.6. Balkan & Baltic Countries
12.2.7. South Asia & Pacific
12.2.8. East Asia
12.2.9. Central Asia
12.2.10. Middle East & Africa
12.3. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Drug Class
13.3.3. By Product
13.3.4. By Indication
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Product
13.4.4. By Indication
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. USAMarket
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Drug Class
13.7.1.2.2. By Product
13.7.1.2.3. By Indication
13.7.1.2.4. By Distribution Channel
13.7.2. Canada Market
13.7.3. Introduction
13.7.4. Market Analysis and Forecast by Market Taxonomy
13.7.4.1.1. By Drug Class
13.7.4.1.2. By Product
13.7.4.1.3. By Indication
13.7.4.1.4. By Distribution Channel
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Product
14.3.4. By Indication
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Product
14.4.4. By Indication
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. Brazil Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Drug Class
14.7.1.2.2. By Product
14.7.1.2.3. By Indication
14.7.1.2.4. By Distribution Channel
14.7.2. Mexico Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Drug Class
14.7.2.2.2. By Product
14.7.2.2.3. By Indication
14.7.2.2.4. By Distribution Channel
14.7.3. Argentina Market
14.7.4. Introduction
14.7.5. Market Analysis and Forecast by Market Taxonomy
14.7.5.1.1. By Drug Class
14.7.5.1.2. By Product
14.7.5.1.3. By Indication
14.7.5.1.4. By Distribution Channel
15. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. France
15.3.1.3. Spain
15.3.1.4. Italy
15.3.1.5. BENELUX
15.3.1.6. Nordic Countries
15.3.1.7. United Kingdom
15.3.2. By Drug Class
15.3.3. By Product
15.3.4. By Indication
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Product
15.4.4. By Indication
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Germany Painkillers Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Drug Class
15.7.1.2.2. By Product
15.7.1.2.3. By Indication
15.7.1.2.4. By Distribution Channel
15.7.2. France Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Drug Class
15.7.2.2.2. By Product
15.7.2.2.3. By Indication
15.7.2.2.4. By Distribution Channel
15.7.3. Spain Market
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Drug Class
15.7.3.2.2. By Product
15.7.3.2.3. By Indication
15.7.3.2.4. By Distribution Channel
15.7.4. Italy Market
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Drug Class
15.7.4.2.2. By Product
15.7.4.2.3. By Indication
15.7.4.2.4. By Distribution Channel
15.7.5. BENELUX Market
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Drug Class
15.7.5.2.2. By Product
15.7.5.2.3. By Indication
15.7.5.2.4. By Distribution Channel
15.7.6. Nordic Countries Market
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Drug Class
15.7.6.2.2. By Product
15.7.6.2.3. By Indication
15.7.6.2.4. By Distribution Channel
15.7.7. UNITED KINGDOMMarket
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Drug Class
15.7.7.2.2. By Product
15.7.7.2.3. By Indication
15.7.7.2.4. By Distribution Channel
16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1.1. Poland
16.3.1.1.2. Hungary
16.3.1.1.3. Romania
16.3.1.1.4. Czech Republic
16.3.1.1.5. Rest of Eastern Europe
16.3.2. By Drug Class
16.3.3. By Product
16.3.4. By Indication
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Drug Class
16.4.2. By Product
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Poland Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Drug Class
16.7.1.2.2. By Product
16.7.1.2.3. By Indication
16.7.1.2.4. By Distribution Channel
16.7.2. Hungary Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Drug Class
16.7.2.2.2. By Product
16.7.2.2.3. By Indication
16.7.2.2.4. By Distribution Channel
16.7.3. Romania Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Drug Class
16.7.3.2.2. By Product
16.7.3.2.3. By Indication
16.7.3.2.4. By Distribution Channel
16.7.4. Czech Republic Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Drug Class
16.7.4.2.2. By Product
16.7.4.2.3. By Indication
16.7.4.2.4. By Distribution Channel
17. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. I India
17.3.1.2. Indonesia
17.3.1.3. Thailand
17.3.1.4. Philippines
17.3.1.5. Malaysia
17.3.1.6. Vietnam
17.3.1.7. Rest of SA
17.3.1.8. Australia & New Zealand
17.3.2. By Drug Class
17.3.3. By Product
17.3.4. By Indication
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Product
17.4.4. By Indication
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. India Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Drug Class
17.7.1.2.2. By Product
17.7.1.2.3. By Indication
17.7.1.2.4. By Distribution Channel
17.7.2. Indonesia Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Drug Class
17.7.2.2.2. By Product
17.7.2.2.3. By Indication
17.7.2.2.4. By Distribution Channel
17.7.3. Thailand Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Drug Class
17.7.3.2.2. By Product
17.7.3.2.3. By Indication
17.7.3.2.4. By Distribution Channel
17.7.4. Philippines Market
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Drug Class
17.7.4.2.2. By Product
17.7.4.2.3. By Indication
17.7.4.2.4. By Distribution Channel
17.7.5. Malaysia Market
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast by Market Taxonomy
17.7.5.2.1. By Drug Class
17.7.5.2.2. By Product
17.7.5.2.3. By Indication
17.7.5.2.4. By Distribution Channel
17.7.6. Vietnam Market
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast by Market Taxonomy
17.7.6.2.1. By Drug Class
17.7.6.2.2. By Product
17.7.6.2.3. By Indication
17.7.6.2.4. By Distribution Channel
17.7.7. Australia & New Zealand Market
17.7.7.1. Introduction
17.7.7.2. Market Analysis and Forecast by Market Taxonomy
17.7.7.2.1. By Drug Class
17.7.7.2.2. By Product
17.7.7.2.3. By Indication
17.7.7.2.4. By Distribution Channel
18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Japan
18.3.1.2. China
18.3.1.3. South Korea
18.3.2. By Drug Class
18.3.3. By Product
18.3.4. By Indication
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Product
18.4.4. By Indication
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Japan Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Drug Class
18.7.1.2.2. By Product
18.7.1.2.3. By Indication
18.7.1.2.4. By Distribution Channel
18.7.2. China Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Drug Class
18.7.2.2.2. By Product
18.7.2.2.3. By Indication
18.7.2.2.4. By Distribution Channel
18.7.3. South Korea Market
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Drug Class
18.7.3.2.2. By Product
18.7.3.2.3. By Indication
18.7.3.2.4. By Distribution Channel
19. Central Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Drug Class
19.3.2. By Product
19.3.3. By Indication
19.3.4. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Drug Class
19.4.2. By Product
19.4.3. By Indication
19.4.4. By Distribution Channel
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
20. Russia & Belarus Market Analysis 2018 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Drug Class
20.3.2. By Product
20.3.3. By Indication
20.3.4. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Drug Class
20.4.2. By Product
20.4.3. By Indication
20.4.4. By Distribution Channel
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
21. Balkan & Baltic Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Drug Class
21.3.2. By Product
21.3.3. By Indication
21.3.4. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Drug Class
21.4.2. By Product
21.4.3. By Indication
21.4.4. By Distribution Channel
21.5. Market Trends
21.6. Drivers and Restraints - Impact Analysis
22. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
22.1. Introduction
22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
22.3.1. By Country
22.3.1.1. GCC Countries
22.3.1.2. Kingdom of Saudi Arabia
22.3.1.3. Türkiye
22.3.1.4. Northern Africa
22.3.1.5. South Africa
22.3.1.6. Israel
22.3.2. By Drug Class
22.3.3. By Product
22.3.4. By Indication
22.3.5. By Distribution Channel
22.4. Market Attractiveness Analysis
22.4.1. By Country
22.4.2. By Drug Class
22.4.3. By Product
22.4.4. By Indication
22.4.5. By Distribution Channel
22.5. Market Trends
22.6. Drivers and Restraints - Impact Analysis
22.7. Country Level Analysis & Forecast
22.7.1. GCC Countries Market
22.7.1.1. Introduction
22.7.1.2. Market Analysis and Forecast by Market Taxonomy
22.7.1.2.1. By Drug Class
22.7.1.2.2. By Product
22.7.1.2.3. By Indication
22.7.1.2.4. By Distribution Channel
22.7.2. Kingdom of Saudi Arabia Market
22.7.2.1. Introduction
22.7.2.2. Market Analysis and Forecast by Market Taxonomy
22.7.2.2.1. By Drug Class
22.7.2.2.2. By Product
22.7.2.2.3. By Indication
22.7.2.2.4. By Distribution Channel
22.7.3. Türkiye Market
22.7.3.1. Introduction
22.7.3.2. Market Analysis and Forecast by Market Taxonomy
22.7.3.2.1. By Drug Class
22.7.3.2.2. By Product
22.7.3.2.3. By Indication
22.7.3.2.4. By Distribution Channel
22.7.4. Northern Africa Market
22.7.4.1. Introduction
22.7.4.2. Market Analysis and Forecast by Market Taxonomy
22.7.4.2.1. By Drug Class
22.7.4.2.2. By Product
22.7.4.2.3. By Indication
22.7.4.2.4. By Distribution Channel
22.7.5. South Africa Market
22.7.5.1. Introduction
22.7.5.2. Market Analysis and Forecast by Market Taxonomy
22.7.5.2.1. By Drug Class
22.7.5.2.2. By Product
22.7.5.2.3. By Indication
22.7.5.2.4. By Distribution Channel
22.7.6. Israel Market
22.7.6.1. Introduction
22.7.6.2. Market Analysis and Forecast by Market Taxonomy
22.7.6.2.1. By Drug Class
22.7.6.2.2. By Product
22.7.6.2.3. By Indication
22.7.6.2.4. By Distribution Channel
23. Market Structure Analysis
23.1. Market Analysis by Tier of Companies
23.2. Market Share Analysis of Top Players (%), 2020-2033
23.3. Market Share Analysis, 2022
24. Competition Analysis
24.1. Competition Dashboard
24.2. Key Development Analysis
24.3. Branding and Promotional Strategies
24.4. Competition Deep Dive
24.4.1. AbbVie Inc. (Allergan plc)
24.4.1.1. Overview
24.4.1.2. Product Portfolio
24.4.1.3. Sales Footprint
24.4.1.4. Key Financials
24.4.1.5. Key Developments
24.4.1.6. SWOT Analysis
24.4.1.7. Strategy Overview
24.4.1.7.1. Marketing Strategy
24.4.1.7.2. Product Strategy
24.4.1.7.3. Channel Strategy
24.4.2. Bristol Myers Squibb Co.
24.4.2.1. Overview
24.4.2.2. Product Portfolio
24.4.2.3. Sales Footprint
24.4.2.4. Key Financials
24.4.2.5. Key Developments
24.4.2.6. SWOT Analysis
24.4.2.7. Strategy Overview
24.4.2.7.1. Marketing Strategy
24.4.2.7.2. Product Strategy
24.4.2.7.3. Channel Strategy
24.4.3. Sanofi S.A.
24.4.3.1. Overview
24.4.3.2. Product Portfolio
24.4.3.3. Sales Footprint
24.4.3.4. Key Financials
24.4.3.5. Key Developments
24.4.3.6. SWOT Analysis
24.4.3.7. Strategy Overview
24.4.3.7.1. Marketing Strategy
24.4.3.7.2. Product Strategy
24.4.3.7.3. Channel Strategy
24.4.4. Boehringer Ingelheim International GmbH
24.4.4.1. Overview
24.4.4.2. Product Portfolio
24.4.4.3. Sales Footprint
24.4.4.4. Key Financials
24.4.4.5. Key Developments
24.4.4.6. SWOT Analysis
24.4.4.7. Strategy Overview
24.4.4.7.1. Marketing Strategy
24.4.4.7.2. Product Strategy
24.4.4.7.3. Channel Strategy
24.4.5. Pfizer Inc.
24.4.5.1. Overview
24.4.5.2. Product Portfolio
24.4.5.3. Sales Footprint
24.4.5.4. Key Financials
24.4.5.5. Key Developments
24.4.5.6. SWOT Analysis
24.4.5.7. Strategy Overview
24.4.5.7.1. Marketing Strategy
24.4.5.7.2. Product Strategy
24.4.5.7.3. Channel Strategy
24.4.6. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
24.4.6.1. Overview
24.4.6.2. Product Portfolio
24.4.6.3. Sales Footprint
24.4.6.4. Key Financials
24.4.6.5. Key Developments
24.4.6.6. SWOT Analysis
24.4.6.7. Strategy Overview
24.4.6.7.1. Marketing Strategy
24.4.6.7.2. Product Strategy
24.4.6.7.3. Channel Strategy
24.4.7. GSK plc.
24.4.7.1. Overview
24.4.7.2. Product Portfolio
24.4.7.3. Sales Footprint
24.4.7.4. Key Financials
24.4.7.5. Key Developments
24.4.7.6. SWOT Analysis
24.4.7.7. Strategy Overview
24.4.7.7.1. Marketing Strategy
24.4.7.7.2. Product Strategy
24.4.7.7.3. Channel Strategy
24.4.8. Abbott Laboratories, Inc.
24.4.8.1. Overview
24.4.8.2. Product Portfolio
24.4.8.3. Sales Footprint
24.4.8.4. Key Financials
24.4.8.5. Key Developments
24.4.8.6. SWOT Analysis
24.4.8.7. Strategy Overview
24.4.8.7.1. Marketing Strategy
24.4.8.7.2. Product Strategy
24.4.8.7.3. Channel Strategy
24.4.9. Novartis AG
24.4.9.1. Overview
24.4.9.2. Product Portfolio
24.4.9.3. Sales Footprint
24.4.9.4. Key Financials
24.4.9.5. Key Developments
24.4.9.6. SWOT Analysis
24.4.9.7. Strategy Overview
24.4.9.7.1. Marketing Strategy
24.4.9.7.2. Product Strategy
24.4.9.7.3. Channel Strategy
24.4.10. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
24.4.10.1. Overview
24.4.10.2. Product Portfolio
24.4.10.3. Sales Footprint
24.4.10.4. Key Financials
24.4.10.5. Key Developments
24.4.10.6. SWOT Analysis
24.4.10.7. Strategy Overview
24.4.10.7.1. Marketing Strategy
24.4.10.7.2. Product Strategy
24.4.10.7.3. Channel Strategy
24.4.11. Sun Pharmaceutical Industries Ltd.
24.4.11.1. Overview
24.4.11.2. Product Portfolio
24.4.11.3. Sales Footprint
24.4.11.4. Key Financials
24.4.11.5. Key Developments
24.4.11.6. SWOT Analysis
24.4.11.7. Strategy Overview
24.4.11.7.1. Marketing Strategy
24.4.11.7.2. Product Strategy
24.4.11.7.3. Channel Strategy
24.4.12. Teva Pharmaceuticals Ltd.
24.4.12.1. Overview
24.4.12.2. Product Portfolio
24.4.12.3. Sales Footprint
24.4.12.4. Key Financials
24.4.12.5. Key Developments
24.4.12.6. SWOT Analysis
24.4.12.7. Strategy Overview
24.4.12.7.1. Marketing Strategy
24.4.12.7.2. Product Strategy
24.4.12.7.3. Channel Strategy
24.4.13. Mallinckrodt Pharmaceuticals
24.4.13.1. Overview
24.4.13.2. Product Portfolio
24.4.13.3. Sales Footprint
24.4.13.4. Key Financials
24.4.13.5. Key Developments
24.4.13.6. SWOT Analysis
24.4.13.7. Strategy Overview
24.4.13.7.1. Marketing Strategy
24.4.13.7.2. Product Strategy
24.4.13.7.3. Channel Strategy
24.4.14. Endo Pharmaceuticals Inc.
24.4.14.1. Overview
24.4.14.2. Product Portfolio
24.4.14.3. Sales Footprint
24.4.14.4. Key Financials
24.4.14.5. Key Developments
24.4.14.6. SWOT Analysis
24.4.14.7. Strategy Overview
24.4.14.7.1. Marketing Strategy
24.4.14.7.2. Product Strategy
24.4.14.7.3. Channel Strategy
24.4.15. Bayer AG
24.4.15.1. Overview
24.4.15.2. Product Portfolio
24.4.15.3. Sales Footprint
24.4.15.4. Key Financials
24.4.15.5. Key Developments
24.4.15.6. SWOT Analysis
24.4.15.7. Strategy Overview
24.4.15.7.1. Marketing Strategy
24.4.15.7.2. Product Strategy
24.4.15.7.3. Channel Strategy
24.4.16. F. Hoffmann-La Roche Ltd.
24.4.16.1. Overview
24.4.16.2. Product Portfolio
24.4.16.3. Sales Footprint
24.4.16.4. Key Financials
24.4.16.5. Key Developments
24.4.16.6. SWOT Analysis
24.4.16.7. Strategy Overview
24.4.16.7.1. Marketing Strategy
24.4.16.7.2. Product Strategy
24.4.16.7.3. Channel Strategy
24.4.17. Procter & Gamble
24.4.17.1. Overview
24.4.17.2. Product Portfolio
24.4.17.3. Sales Footprint
24.4.17.4. Key Financials
24.4.17.5. Key Developments
24.4.17.6. SWOT Analysis
24.4.17.7. Strategy Overview
24.4.17.7.1. Marketing Strategy
24.4.17.7.2. Product Strategy
24.4.17.7.3. Channel Strategy
24.4.18. AstraZeneca
24.4.18.1. Overview
24.4.18.2. Product Portfolio
24.4.18.3. Sales Footprint
24.4.18.4. Key Financials
24.4.18.5. Key Developments
24.4.18.6. SWOT Analysis
24.4.18.7. Strategy Overview
24.4.18.7.1. Marketing Strategy
24.4.18.7.2. Product Strategy
24.4.18.7.3. Channel Strategy
24.4.19. Cardinal Health
24.4.19.1. Overview
24.4.19.2. Product Portfolio
24.4.19.3. Sales Footprint
24.4.19.4. Key Financials
24.4.19.5. Key Developments
24.4.19.6. SWOT Analysis
24.4.19.7. Strategy Overview
24.4.19.7.1. Marketing Strategy
24.4.19.7.2. Product Strategy
24.4.19.7.3. Channel Strategy
24.4.20. Perrigo Company Plc.
24.4.20.1. Overview
24.4.20.2. Product Portfolio
24.4.20.3. Sales Footprint
24.4.20.4. Key Financials
24.4.20.5. Key Developments
24.4.20.6. SWOT Analysis
24.4.20.7. Strategy Overview
24.4.20.7.1. Marketing Strategy
24.4.20.7.2. Product Strategy
24.4.20.7.3. Channel Strategy
24.4.21. Bausch Health Companies Inc.
24.4.21.1. Overview
24.4.21.2. Product Portfolio
24.4.21.3. Sales Footprint
24.4.21.4. Key Financials
24.4.21.5. Key Developments
24.4.21.6. SWOT Analysis
24.4.21.7. Strategy Overview
24.4.21.7.1. Marketing Strategy
24.4.21.7.2. Product Strategy
24.4.21.7.3. Channel Strategy
24.4.22. Viatris
24.4.22.1. Overview
24.4.22.2. Product Portfolio
24.4.22.3. Sales Footprint
24.4.22.4. Key Financials
24.4.22.5. Key Developments
24.4.22.6. SWOT Analysis
24.4.22.7. Strategy Overview
24.4.22.7.1. Marketing Strategy
24.4.22.7.2. Product Strategy
24.4.22.7.3. Channel Strategy
24.4.23. Amillioneal Pharmaceuticals
24.4.23.1. Overview
24.4.23.2. Product Portfolio
24.4.23.3. Sales Footprint
24.4.23.4. Key Financials
24.4.23.5. Key Developments
24.4.23.6. SWOT Analysis
24.4.23.7. Strategy Overview
24.4.23.7.1. Marketing Strategy
24.4.23.7.2. Product Strategy
24.4.23.7.3. Channel Strategy
24.4.24. Purdue Pharmaceuticals L.P.
24.4.24.1. Overview
24.4.24.2. Product Portfolio
24.4.24.3. Sales Footprint
24.4.24.4. Key Financials
24.4.24.5. Key Developments
24.4.24.6. SWOT Analysis
24.4.24.7. Strategy Overview
24.4.24.7.1. Marketing Strategy
24.4.24.7.2. Product Strategy
24.4.24.7.3. Channel Strategy
25. Assumptions and Acronyms Used
26. Research Methodology
Explore Healthcare Insights
View Reports
Pain Therapeutic Injectables Market
